Fate Therapeutics Jumps 28% on Promising iPSC-Derived NK Cell Phase I Data
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company based in San Diego, California. The company focuses on off-the-shelf, induced pluripotent stem cell (iPSC)-derived therapies for cancer and autoimmune diseases. Fate utilizes a proprietary iPSC platform to engineer homogeneous cell products with multiplexed controls of cell function, allowing for the delivery of multiple therapeutic mechanisms in a single dose.
Corporate Structure and Team
Fate Therapeutics holds exclusive licensing and co-development rights to over 350 issued patents and 150 pending applications associated with its iPSC product platform. The leadership team comprises executives with backgrounds in cell therapy manufacturing, clinical development, and translational research. The workforce consists of immunologists, molecular biologists, process engineers, and regulatory affairs specialists. Fate operates research and manufacturing facilities in San Diego, with collaborations extending to North America, Europe, and Asia.
iPSC therapy by Larm Rmah
Recent Developments and News
- On June 28, 2022, Fate and Ono Pharmaceutical Co., Ltd. expanded their collaboration to include iPSC-derived CAR-NK cell therapies for solid tumors, alongside CAR-T cell candidates. Under the revised agreement, Fate retains manufacturing rights and co-commercialization options in the United States and Europe.
- Fate’s Quality Assurance team volunteered at Ronald McDonald House Charities of San Diego, supporting families of hospitalized children at Rady Children’s Hospital, as noted in a LinkedIn post.
- On August 12, 2025, shares of FATE closed at $1.2001, reflecting an increase of 28.17% with a trading volume of 2,974,610 shares, following the release of interim Phase I data related to its lead NK cell candidate.
Financial and Strategic Analysis
Key metrics for the twelve months ending June 30, 2025:
| Metric | Value |
|---|---|
| Stock Price (8/12/2025) | $1.2001 (+28.17% day) |
| Market Capitalization | $107.3 million |
| Revenue (TTM) | $13.34 million |
| Net Income (TTM) | –$175.88 million |
| Total Cash (MRQ) | $240.42 million |
| Total Debt/Equity (MRQ) | 28.89% |
| Beta (5Y monthly) | 2.24 |
| Price/Sales (TTM) | 8.29 |
| Price/Book (MRQ) | 0.37 |
| 1-Year Target Estimate | $5.62 |
Fate’s cash position of $240 million provides sufficient resources to advance multiple clinical programs, while the levered free cash flow stands at –$76.9 million over the past twelve months. A high beta of 2.24 indicates volatility, characteristic of early-stage biotech companies. The absence of positive earnings per share (–$1.49 TTM) is typical for firms in intensive research and development phases. Strategic partnerships, particularly with Ono, and an extensive patent portfolio contribute to risk mitigation and global development opportunities.
Market Position and Industry Context
The global cell therapy market is marked by ongoing innovation in off-the-shelf products, with various competitors developing allogeneic CAR-T and CAR-NK platforms. Fate’s iPSC-derived approach differs from autologous therapies by promoting batch uniformity, scalable manufacturing, and possible cost reductions. Its pipeline includes first-in-class CAR-T and CAR-NK candidates aimed at solid tumors, as well as programs addressing autoimmune indications such as antineutrophilic cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myositis, and systemic sclerosis. Collaborations with pharmaceutical partners and academic institutions enhance access to new targets and co-development funding.
TL;DR
Fate’s stock increased by 28.17% on August 12, 2025, closing at $1.20 following announcements regarding interim Phase I data for its iPSC-derived NK cell therapy. The company holds $240 million in cash against a $76.9 million annual cash burn, which facilitates multiple clinical and preclinical initiatives. Its expanded collaboration with Ono Pharmaceutical and comprehensive patent estate support the development of off-the-shelf CAR-T and CAR-NK products. Investors will monitor forthcoming clinical readouts and partnership milestones as potential indicators toward its $5.62 one-year price target.